Dr. Young is the Chairman at Novavax, Inc., Chairman at Targeted Microwave Solutions, Inc. and sits on the board of directors at 3-V Biosciences, Inc. Dr. Young has over 30 years of experience in the fields of molecular genetics, microbiology, immunology and pharmaceutical development. Prior AstraZeneca acquisition of MedImmune for 15.8 billion dollars, Dr. Young was MedImmune’s President of Research and Development. Dr. Young received his doctorate in microbiology and immunology from Baylor College of Medicine in Houston, Texas, and in 2005 was awarded the Albert B. Sabin Humanitarian Award.
Chairman, Novavax, Inc. (Nasdaq:NVAX)
Co-Founder Medlmmune prior to acquiring MedImmune for 15.8 billion dollars AstraZeneca
Over 30 years of experience in pharmaceutical development
Holds a doctorate in microbiology and immunology from Baylor College of Medicine in Houston, Texas,
Awarded the Albert B. Sabin Humanitarian Award in 2005
We Provide Investors Unique Access to Diverse, High Potential, Growth-Ready Assets In North America’s Emerging Cannabis Market.